Genetics of community-acquired pneumonia

被引:12
|
作者
Wunderink, RG
Waterer, GW
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA
[2] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
关键词
genetics; community-acquired pneumonia; polymorphism; tumor necrosis factor; lymphotoxin alpha;
D O I
10.1055/s-2005-925522
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The variable clinical presentation of community-acquired pneumonia (CAP) suggests a genetic predisposition. Specific mutations or polymorphisms in host response genes such as pattern recognition molecules (PRMs), inflammatory molecules, and the coagulation system are likely to play a role in this variable response to CAP. Mannose-binding lectin polymorphisms appear to play a more dominant role in CAP than other PRMs, such as the Toll-like receptors (TLRs). The role of tumor necrosis factor (TNF) and lymphotoxin alpha (LTA) polymorphisms remain unclear despite extensive study whereas interleukin (IL)-10 and IL-1 receptor antagonist polymorphisms appear to play an important role in the anti-inflammatory response. Coagulation gene polymorphisms are likely important as well. The real value of these genetic studies in CAP and other severe infections will be when the management of an individual patient can be optimized by therapy based on the individual's genotype for molecules important in outcome.
引用
收藏
页码:553 / 562
页数:10
相关论文
共 50 条
  • [41] Outpatient management of community-acquired pneumonia
    Froes, Filipe
    Pereira, Joao Goncalves
    Povoa, Pedro
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (03) : 249 - 256
  • [42] Clarithromycin in the management of community-acquired pneumonia
    McCarty, JM
    CLINICAL THERAPEUTICS, 2000, 22 (03) : 281 - 294
  • [43] Community-Acquired Pneumonia: An Unfinished Battle
    Nair, Girish B.
    Niederman, Michael S.
    MEDICAL CLINICS OF NORTH AMERICA, 2011, 95 (06) : 1143 - +
  • [44] New antibiotics for community-acquired pneumonia
    Kollef, Marin H.
    Betthauser, Kevin D.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (02) : 169 - 175
  • [45] The management of community-acquired pneumonia in the elderly
    Faverio, Paola
    Aliberti, Stefano
    Bellelli, Giuseppe
    Suigo, Giulia
    Lonni, Sara
    Pesci, Alberto
    Restrepo, Marcos I.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (04) : 312 - 319
  • [46] Tigecycline in the Treatment of Community-Acquired Pneumonia
    Curcio, Daniel
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1275 - 1289
  • [47] Antibiotic stewardship in community-acquired pneumonia
    Viasus, Diego
    Vecino-Moreno, Milly
    De La Hoz, Juan M.
    Carratala, Jordi
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2017, 15 (04) : 351 - 359
  • [48] Guidelines to Manage Community-Acquired Pneumonia
    Wunderink, Richard G.
    CLINICS IN CHEST MEDICINE, 2018, 39 (04) : 723 - +
  • [49] Controversies in the Management of Community-Acquired Pneumonia
    Singh, Kanal
    Jagadeesan, Rajasekar
    CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS, 2016, 4 (03): : 126 - 135
  • [50] MORTALITY PREDICTORS IN COMMUNITY-ACQUIRED PNEUMONIA
    Tanimowo, M. O.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2009, 12 (03) : 298 - 301